Image Source: IPO Watch
Anthem Biosciences, a leading CRDMO player in India, is set to launch its ₹3,395 crore initial public offering (IPO) from July 14 to July 16. The IPO is entirely an offerforsale (OFS) of 5.96 crore shares by existing shareholders, with no fresh issue component.
Key Dates and Structure:
-
Anchor investor bidding: July 11
-
Public subscription window: July 14 to July 16
-
Allotment finalization: July 17
-
Refunds and credit to demat accounts: July 18
-
Listing on BSE and NSE: July 21
IPO Details and Investor Allocation:
-
Price band: ₹540 to ₹570 per share (face value ₹2)
-
Lot size: 26 shares; minimum investment ₹14,820 for retail investors
-
Allocation: 50% to QIBs, 15% to NIIs, 35% to retail investors
-
₹8.25 crore worth of shares reserved for eligible employees
Company Snapshot:
-
Founded in 2006, Anthem Biosciences operates across drug discovery, development, and manufacturing
-
Specializes in fermentationbased APIs including probiotics, enzymes, peptides, and biosimilars
-
Serves over 550 clients across 44 countries, with top five contributing 71% of FY25 revenue
-
FY25 revenue: ₹1,844 crore (up 30% YoY); PAT: ₹451 crore (up 23%)
-
Operates two facilities in Karnataka, with a third under construction
Why It Matters:
With strong financials, global reach, and regulatory accreditations, Anthem’s IPO offers investors exposure to India’s expanding pharmaceutical outsourcing sector.
Sources: Livemint, Economic Times, Moneycontrol, Zee Business, Upstox News, IPOWatch India
Advertisement
STORIES YOU MAY LIKE
Image Source: PA Wealth
Image Source: Construction World
Advertisement